Patient Video Surveillance System Provides High-Definition Real-Time
Imaging at the Bedside
IRVINE, Calif.--(BUSINESS WIRE)--Mar. 2, 2016--
Masimo
(NASDAQ: MASI) today announced the debut of SafetyNet™ Surveillance at
the HIMSS
(Healthcare Information and Management Systems Society) 2016 Annual
Conference and Exhibition in Las Vegas.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20160302005294/en/
Masimo Root with SafetyNet Surveillance (Photo: Business Wire)
SafetyNet Surveillance is a video surveillance system that provides
real-time video images of a patient’s room, including the patient with
connected monitoring devices, to a central station. Masimo SafetyNet
Surveillance is a software option for Masimo’s Patient SafetyNet system,
adding existing communication technology to central monitoring.
The camera delivers a high-resolution, high-frame rate video feed to the
Patient SafetyNet view-station. An external mechanical lens cap lets
patients or their visitors disable the camera at any time. Two-way audio
is available to allow the caregiver to listen and communicate with the
patient. The system utilizes the existing hospital IT network and can
provide viewing of images in the same care area.
“Video surveillance that is not cost prohibitive adds an exciting new
dimension to hospital healthcare systems,” said Joe Kiani, Founder and
CEO of Masimo. “SafetyNet Surveillance combines innovations we take for
granted in our everyday lives—real-time video and two-way audio
communication—with top-tier noninvasive medical technology to deliver a
holistic system cost effectively. We hope this enhancement to Patient
SafetyNet will improve the quality and safety of patient care and help
reduce costs.”
For more information on Masimo and its products, go to www.masimo.com.
@MasimoInnovates
| #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care by taking noninvasive monitoring to new sites
and applications. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. The benefits of Masimo SET® have
been proven in more than 100 independent and objective studies and it is
estimated to be used on more than 100 million patients in leading
hospitals and other healthcare settings around the world. In 2005,
Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing
noninvasive and continuous monitoring of blood constituents that
previously could only be measured invasively, including total hemoglobin
(SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and more recently, Pleth Variability Index
(PVI®) and Oxygen Reserve Index (ORI™), in addition to SpO2, pulse rate,
and perfusion index (PI). In 2014, Masimo introduced Root®, an intuitive
open architecture patient monitoring and connectivity platform designed
to speed the pace of innovation and reduce the cost of care. Masimo is
also taking an active leadership role in mHealth with products such as
the Radius-7™ wearable patient monitor and the MightySat™ fingertip
pulse oximeter. Additional information about Masimo and its products may
be found at www.masimo.com.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, statements regarding the potential
effectiveness of Masimo’s SafetyNet™ Surveillance system. These
forward-looking statements are based on current expectations about
future events affecting us and are subject to risks and uncertainties,
all of which are difficult to predict and many of which are beyond our
control and could cause our actual results to differ materially and
adversely from those expressed in our forward-looking statements as a
result of various risk factors, including, but not limited to: risks
related to our assumptions regarding the repeatability of clinical
results; risks related to our belief that Masimo's unique noninvasive
measurement technologies, including SafetyNet™ Surveillance, contribute
to positive clinical outcomes and patient safety; risks related to our
belief that Masimo noninvasive medical breakthroughs provide
cost-effective solutions with comparable accuracy and unique advantages,
including: immediate and continuous results that enable earlier
treatment without causing invasive trauma in all patients and in every
clinical situation; as well as other factors discussed in the "Risk
Factors" section of our most recent reports filed with the Securities
and Exchange Commission (“SEC”), which may be obtained for free at the
SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160302005294/en/
Source: Masimo
Media:
Masimo
Irene Paigah, 858-859-7001
irenep@masimo.com